Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.39 |
| ▸ | CASP1 | P29466 | 7/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.36 |
| ▸ | MEN1 | O00255 | 6/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.36 |
| ▸ | MAPT | P10636 | 6/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.36 |
| ▸ | LMNA | P02545 | 5/20 | 0.36 |
| ▸ | CASP7 | P55210 | 4/20 | 0.36 |
| ▸ | HTT | P42858 | 4/20 | 0.36 |
| ▸ | BRCA1 | P38398 | 3/20 | 0.36 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.36 |
| ▸ | USP2 | O75604 | 2/20 | 0.36 |
| ▸ | APEX1 | P27695 | 1/20 | 0.36 |
| ▸ | HBB | P68871 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 4/20 | 0.35 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.35 |
| ▸ | GLA | P06280 | 3/20 | 0.35 |
| ▸ | HPGD | P15428 | 3/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17646474 | 0.78 | KDM4E (0.33) | ALDH1A1KDM4EMAPTSMN1; SMN2LMNA | |
| SCHEMBL7139095 | 0.74 | GAA (0.43) | ALDH1A1CASP1KDM4EMEN1KMT2A | |
| SCHEMBL6023304 | 0.74 | GAA (0.35) | CYP3A4TSHRGAANPC1TP53 | |
| SCHEMBL5784218 | 0.72 | MAPT (0.53) | ALDH1A1KDM4EKMT2AMAPTSMN1; SMN2 | |
| SCHEMBL11688864 | 0.71 | CASP1 (0.41) | ALDH1A1CASP1KDM4EMEN1KMT2A | |
| SCHEMBL11999964 | 0.69 | KDM4E (0.49) | ALDH1A1KDM4EMEN1KMT2AMAPT | |
| SCHEMBL6024316 | 0.68 | ALDH1A1 (0.35) | ALDH1A1KDM4EMEN1KMT2AMAPT | |
| SCHEMBL11803253 | 0.67 | CASP1 (0.35) | ALDH1A1CASP1KDM4EMEN1KMT2A | |
| SCHEMBL25985955 | 0.66 | ALDH1A1 (0.59) | ALDH1A1CASP1KDM4EMEN1KMT2A | |
| SCHEMBL1286632 | 0.65 | MEN1 (0.47) | ALDH1A1CASP1KDM4EMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7538121-B2 | Vanilloid receptor modulators | GLAXO GROUP LIMITED (GB) | 2009-05-26 | — | — | US | disclosed |
| EP-2033953-A1 | Vanilloid receptor modulators | Glaxo Group Limited (GB) | 2009-03-11 | — | — | EP | disclosed |
| CN-100374423-C | Process for the preparation of 4-methyl-7-aminoquinolones | CIBA SC HOLDING CO LTD (CH) | 2008-03-12 | — | — | CN | disclosed |
| CN-100374423-C | Process for the preparation of 4-methyl-7-aminoquinolones | CIBA SC HOLDING CO LTD (CH) | 2008-03-12 | — | — | CN | disclosed |
| US-7144993-B2 | Process for the preparation of 4-methyl-7-aminoquinolones | CIBA SPECIALTY CHEMICALS CORP. (US) | 2006-12-05 | — | — | US | disclosed |
| US-7144993-B2 | Process for the preparation of 4-methyl-7-aminoquinolones | CIBA SPECIALTY CHEMICALS CORP. (US) | 2006-12-05 | — | — | US | disclosed |
| US-20060142333-A1 | Vanilloid receptor modulators | MACDONALD GREGOR J | 2006-06-29 | — | — | US | disclosed |
| US-20050222397-A1 | Process for the preparation of 4-methyl-7-aminoquinolones | CIBA SPECIALTY CHEMICALS CORP. | 2005-10-06 | — | — | US | disclosed |
| US-20050222397-A1 | Process for the preparation of 4-methyl-7-aminoquinolones | CIBA SPECIALTY CHEMICALS CORP. | 2005-10-06 | — | — | US | disclosed |
| CN-1602301-A | Preparation process of 4-methyl-7-aminoquinolone | CIBA SC HOLDING AG (CH) | 2005-03-30 | — | — | CN | disclosed |
| CN-1602301-A | Preparation process of 4-methyl-7-aminoquinolone | CIBA SC HOLDING AG (CH) | 2005-03-30 | — | — | CN | disclosed |
| EP-1480954-A1 | VANILLOID RECEPTOR MODULATORS | GLAXO GROUP LIMITED (GB) | 2004-12-01 | — | — | EP | disclosed |
| EP-1453809-A1 | PROCESS FOR THE PREPARATION OF 4-METHYL-7-AMINOQUINOLONES | Ciba SC Holding AG (CH) | 2004-09-08 | — | — | EP | disclosed |
| WO-2003068749-A1 | VANILLOID RECEPTOR MODULATORS | GLAXO GROUP LIMITED (GB) | 2003-08-21 | — | — | WO | disclosed |
| WO-2003050089-A1 | PROCESS FOR THE PREPARATION OF 4-METHYL-7-AMINOQUINOLONES | CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) | 2003-06-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060142333-A1 | Vanilloid receptor modulators | TRPV1, NPSR1, TRPV3 | ALDH1A1 2107/4885CASP1 4536/4885KDM4E 3923/4885 |
| US-20050222397-A1 | Process for the preparation of 4-methyl-7-aminoquinolones | CBR1, CBR3, MRPL21 | ALDH1A1 2050/4885CASP1 3441/4885KDM4E 2804/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.